TrialThe pharmacogenomics journal2024

Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension.

Julia C F Quintanilha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.